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Antibody-drug conjugates (ADCs) are an emerging novel class of anticancer treatment agents that combines the selectivity of
targeted treatment with the cytotoxic potency of chemotherapy drugs. New linker technology associated with novel highly potent
cytotoxic payloads has permitted the development of more effective and safe ADCs. In recent years, two ADCs have been
licensed, T-DM1 and brentuximab vedotin, and are already establishing their place in cancer treatment. A plethora of ADCs are
being investigated in phases I and II trials, emerging data of which appears promising. As we deepen our understanding of what
makes a successful ADC, an increasing number of ADCs will likely become viable treatment options as single agents or in
combination with chemotherapy. This review will present the philosophy underlying ADCs, their main characteristics and current
research developments with a focus on ADCs in solid tumours.
Paul Ehrlich’s vision of a rational targeted strategy against invading
microbes or malignant cells has been a driving research throughout
the past century, bringing a scientific and therapeutic revolution in
cancer treatment. Although antibody-drug conjugates (ADCs)
have been under investigation for decades, it is only recently with
the advent of significant advances in engineering new linker and
conjugation technologies together with highly potent cytotoxic
drugs that we have realised the ADC’s true potential (Panowksi
et al, 2014). Monoclonal antibodies have proved to have an
important role in cancer treatment with drugs such as trastuzu-
mab, pertuzumab, cetuximab and rituximab becoming the
standard of care in selected solid tumours and lymphomas. Classic
chemotherapy, the mainstay of anticancer treatment, demonstrates
limited selectivity against cancer cells leading to a small therapeutic
window, thus limiting its efficacy.
Antibody-drug conjugates could bring these two classes of drugs
with their complementing properties together, in creating a highly
selective and highly cytotoxic cancer treatment with an increased
therapeutic window, as envisaged by Paul Ehrlich (Hughes, 2010).
Looking back into the reasons for previous failures gives us an
opportunity to identify the crucial characteristics that will make
ADC an effective anticancer treatment. The low chemotherapy
drug potency, unstable linkers and low antigen selectivity are the
most commonly identified weaknesses limiting the efficacy of an
ADC (Perez et al, 2014). In addition, in some of the first clinical
trials murine antibodies were used leading to high rates of
immunogenicity and, therefore, to low efficacy (Hughes, 2010).
Antibody-drug conjugates have a complex structure with many
moving parts, each of which has different properties and desirable
characteristics. An ADC can be divided into three main structural
units: the antibody, the cytotoxic agent and the linker, which will
be discussed below.
ANTIBODY-DRUG CONJUGATES
Target antigen. The ideal target antigen should be: (a) highly
expressed with limited heterogeneity across the tumour and with
low normal tissue expression, for example, T-DM1 targets HER-2,
a receptor that reaches levels of expression of 2 106 on HER-2-
positive cancer cells compared with 2 104 on other cells (Shefet-
Carasso and Benhar, 2015); (b) there should be minimal antigen
shedding to prevent the antibody binding to its target within the
circulation; and (c) the antibody should be well internalised by
receptor-mediated endocytosis and should not be modulated
during endocytosis. The target antigen should not be down-
regulated after treatment with the ADC (Mack et al, 2014). The
minimum threshold of the different variables that are required to a
make a tumour antigen an effective target is still undetermined
and interdependent. Studies in lymphoma and prostate cancer
have shown that a minimum value of tumour-antigen density is a
prerequisite for ADC efficacy. The biomarker analysis study
for TDM1 showed that although it was active across different
HER-2 expression subgroups, patients with tumours who
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expressed HER-2 more highly derived the greatest benefit (Baselga
et al, 2013). The desirable cutoff value of antigen expression varies
greatly and depends on other target antigen properties such as the
internalisation rate and binding affinity, as well as other ADC
characteristics, such as cytotoxic payload and linker stability. There
is evidence that ADCs can be effective even when they target
antigens with low expression given minimal normal tissue
expression (Perez et al, 2014). The problem of non-homogeneous
expression of the target antigen in solid tumours could potentially
be addressed by the bystander effect, that is, the process by which
membrane-permeable free cytotoxic payload is able to induce cell
death to the neighbouring cells after being internalised and cleaved
from the linker. Conversely, the bystander effect can increase the
ADCs off-target systemic toxicity. Various factors can affect the
rate of internalisation of the ADC in the cancer cell, which is a
poorly understood process. One such factor is the epitope on the
target antigen. For example, different epitopes of the HER-2
receptor have resulted in significantly different rates of internalisa-
tion and degradation of the mAb-Ag molecule. In addition, there
are other difficulties while targeting cancer cell surface antigens,
such as the high interstitial tumour pressure, downregulation of the
antigen and the presence of other physical and kinetic barriers that
diminish the cytotoxic payload uptake (Mack et al, 2014; Perez
et al, 2014). Although most licensed or at an advanced research
stage ADCs target tumour antigens, alternative approaches are
actively being investigated to overcome some of the above
mentioned limitations (Casi and Neri, 2012).
Another approach is to target antigens in stroma and
vasculature. There is evidence in the preclinical and clinical setting
that components of the neovasculature subendothelial extracellular
matrix and of the tumour stroma could be valuable target antigens.
A characteristic example is the extra-domain B (ED-B) of
fibronectin which is a marker of angiogenesis, specifically highly
expressed in vasculature of aggressive solid tumours (Palumbo
et al, 2011) (Figure 1). The human mAb L19 which targets the ED-
B has been combined with different effector molecules and has
been studied extensively as a potential ADC. This target was
successfully exploited by conjugating it with tubulin inhibitors
showing that non-internalising vascular targeting ADCs could
offer other treatment approaches (Perrino et al, 2014), (Table 1).
A further interesting approach to targeting antigens is to target
the tumour-initiating cells or cancer stem cells (TICs). The
hypothesis is that since TICs comprise an aggressive sub-population
of tumour cells that are responsible for tumour growth, metastasis
and recurrence, targeting these cells will have a big impact on the
disease control (Visvader and Lindeman, 2008). Sapra et al (2013)
have developed an ADC combined with a tubulin inhibitor that
targets 5T4 oncofetal antigen, which is an antigen expressed in TICs
in NSCLC and has been associated with an invasive phenotype. A
phase I trial investigating this ADC is currently recruiting patients
with NSCLC and other solid tumours (Figure 1).
Antibody selection. Antibody engineering has made break-
throughs over recent years making it feasible to produce humanised
and fully human antibodies as the basic components of ADCs. The
early generation ADCs used murine antibodies causing significant
immunogenicity, with many patients producing human anti-mouse
antibodies thus reducing the efficacy of treatment.
The most commonly used antibody format currently is human
IgG isotypes and in particular IgG1 (Hughes, 2010; Perez et al,
2014). The antibodies once part of the ADC can retain their original
properties and activate immune functions such as antibody-
dependent cellular cytotoxicity (ADCC) or complement-dependent
cytotoxicity (Perez et al, 2014). They could still act as receptor
inhibitors or signal modulators. One example of complementary
action is T-DM1 whose Ab’s retain effector functions have been
shown to activate ADCC (Junttila et al, 2011). The independent
function of the antibody is not always beneficial and complementary
to ADC efficacy, especially when Ab binding is sufficient to produce
a cytotoxic effect. The Ab’s independent effector functions could
lead to increased toxicity, reduced tumour localisation and
internalisation of the ADC (Sapra and Shor, 2013).
Linkers and conjugation. The linker plays a crucial role since its
properties greatly influence the ADC’s pharmacokinetics, ther-
apeutic index and efficacy (Hughes, 2010; Flygare et al, 2013;
Shefet-Carasso and Benhar, 2015). The ideal linker should be stable
so that the ADC does not release the cytotoxic drug before
reaching its target and causing off-target toxicity. At the same time
it should be able to release the drug efficiently once internalised
(Teicher and Chari, 2011).
Another important factor is how many of the drug molecules will
be loaded onto the antibody: the drug-antibody ratio (DAR).
Attaching too few of the drug molecules will lead to decreased
efficacy. Attach too many and the ADC will become unstable with
altered pharmacokinetic properties, increased plasma clearance,
reduced half-life and increased systemic toxicity (Perez et al, 2014).
The currently licensed ADCs with proven activity are produced by
nonspecific conjugation to lysine residues and to some degree
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Figure 1. Target antigens for ADCs in solid tumours.
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consist of an undesirable heterogeneous mixture of ADCs contain-
ing drug molecules with high DAR. There are ongoing efforts for
more homogeneous ADCs with increased number of drug molecules
stably linked to the Ab. The optimal DAR is undetermined and
highly dependent on other ADC variables; however, more
commonly the ADCs aim to attain a DAR close to 4. (Hamblett
et al, 2004; Teicher and Chari, 2011). Site-specific conjugation, has
been an important step in ADC development, enabled the
production of homogeneous ADCs with the desired and pre-
specified DAR by using techniques such as engineered cysteine
Table 1. Target antigens in solid tumours under research
Name ADC Lead indication
Target antigens overexpressed in cancer cells
GPNMB Glembatumumab vedotin [1] Breast cancer and melanoma
CD56 Lorvotuzumab mertansine (IMGN-901) [2] SCLC
TACSTD2 (TROP2) sacituzumab govitecan (IMMU-132) [3] TNBC and pancreatic cancer
CEACAM5 Labetuzumab SN-38 [4] Colorectal cancer
Folate receptor-a  Mirvetuximab soravtansine (IMGN-853) [5]
 Vintafolide [6]
Ovarian and endometrial cancer
Mucin 1 (Sialoglycotope CA6) SAR-566658 [7] Breast, ovarian, cervical, lung and pancreatic cancer
STEAP1 Vandortuzumab vedotin RG-7450 [8] Prostate cancer
Mesothelin  DMOT4039A [9]
 Anetumab ravtensine (BAY-94–9343) [10]
Ovarian, pancreatic cancer and mesothelioma
Nectin 4  Enfortumab vedotin (ASG-22M6E) [11]
 ASC-22CE [12]
Bladder, breast, lung and pancreatic cancer
ENPP3 AGS-16M8F [13] Renal cell carcinoma, liver carcinoma and prostate cancer
Guanylyl cyclase C (GCC) Indusatumab vedotin (MLN-0264) [14] Pancreatic and colorectal cancer
SLC44A4 ASG-5ME [15] Pancreatic, gastric and prostate cancer
NaPi2b  anti-NaPi2b ADC, Lifastuzumab vedotin [16] Non-small cell lung cancer and platinum-resistant ovarian cancer
CD70 (TNFSF7)  DNIB0600A [17]
 AMG-172 [18]
 MDX-1203 [19]
 Vorsetuzumab mafodotin SGN-75 [20]
Renal cell carcinoma
CA9, Carbonic anhydrase BAY79–4620 [21] Solid tumours
5T4 (TPBG) PF 06263507 [22] Solid tumours
SLTRK6 ASG-15ME [23] Bladder cancer
SC-16 (anti-Fyn3) SC16LD6.5 [24] SCLC
NSCLC and ovarian cancer
Tissue factor HuMax-TF-ADC (TF-011-MMAE) [25] Solid tumours
LIV-1 (ZIP6) SGN-LIV1A [26] Breast cancer
P-Cadherin PCA062 [27] Solid tumours
PSMA  MLN2704 [28]
 PSMA-ADC [29]
Prostate cancer
Target antigens in the tumour vasculature and stroma
Fibronectin Extra-domain B
(ED-B)
Human mAb L19 and F8 [30] Solid tumours
Endothelin receptor ETB RG-7636 [31] Melanoma
VEGFR2 (CD309) Anti-VEGFR-2ScFv-As2O3-stealth Nanoparticles [32] Solid tumours
Tenascin c Anti-TnC-A1 antibody SIP(F16) [33] Solid tumours
Collagen IV Cytotoxic immunoconjugates [34] Solid tumours
Periostin Anti-periostin antibody [35] Solid tumours
Target antigens regulated from driver oncogenes
HER 2  T-DM1[36]
 ARX788 [37]
 SYD985 [38]
Breast cancer
EGFR  ABT-414 [39]
 IMGN289 [40]
 AMG-595 [41]
Glioblastoma, NSCLC, head and neck, breast, oesophageal
Target antigens in haematological malignancies
CD30  Brentuximab vedotin [42]
 Iratumumab MDX-060 [43]
HL and ALCL
CD22  Inotuzumab ozogamicin (CMC-544) [44]
 Pinatuzumab vedotin [45]
 Epratuzumab SN38 [46]
NHL and ALL
CD79b  Polatuzumab vedotin [47] DLBCL and follicular NHL
CD19  Coltuximab ravtansine [48]
 SAR-3419 [49]
DLBCL and ALL
CD138 Indatuximab ravtansine [50] Multiple myeloma
CD74 Milatuzumab doxorubicin [51] CLL, NHL and multiple myeloma
CD37 IMGN-529 [52] NHL and CLL
CD33  IMGN779 [53]
 SGN CD33 A [54]
AML
CD19 SGN-CD19A [55] ALL and NHL,
CD98 IGN523 [56] AML
Abbreviations: ADC¼ antibody-drug conjugate; ALL¼ acute lymphocytic leukemia; AML¼ acute myelogenous leukemia; CLL¼ chronic lymphocytic leukemia; DLBCL¼diffuse large B-cell
lymphoma; HL¼Hodgkin lymphoma; NHL¼ non-Hodgkin lymphoma; NSCLC¼ non-small cell lung cancer; SCLC¼ small cell lung cancer; TNBC¼ triple-negative breast cancer. Please refer to
the Supplementary Data File for all references cited in this table.
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residue, non-canonical amino acid incorporation or modification of
peptide tags (Panowksi et al, 2014; Agarwal and Bertozzi, 2015).
Linkers can be divided in non-cleavable and cleavable. Non-
cleavable linkers have the characteristic that following ADC
lysosomal degradation the cytotoxic payload remains active while
still being attached to the linker and an amino acid residue. T-DM1
is an ADC that uses a non-cleavable linker (Junttila et al, 2011;
Shefet-Carasso and Benhar, 2015).
Cleavable linkers use different methods to release cytotoxic drug,
increasing the possibility of the bystander effect. There are acid-
sensitive linkers that will release the free drug in the low pH
conditions in lysosomes or endosomes. Such a mechanism was used
by gemtuzumab ozogamicin and its linker was characterised by
certain plasma instability (Hamann et al, 2002; Shefet-Carasso and
Benhar, 2015). Inotuzumab ozogamicin, now in phase II trials, uses
the same linker and it is more stable (Boghaert et al, 2008). Another
type of cleavable linker are lysosomal protease-sensitive linkers with
the licensed example of brentuximab vedotin (Senter and Sievers,
2012). A third type are glutathione-sensitive linkers that benefit
from the higher concentration of glutathione in tumour cells. (Sapra
et al, 2011). Each approach has different advantages and
disadvantages, so the choice of the linker can only be determined
by taking into account all the other components of the ADC.
Cytotoxic payload. To create an effective ADC, it is imperative to
have a potent cytotoxic payload. The first generation of ADCs used
classical chemotherapy drugs such as doxorubicin and methotrex-
ate with the benefit of a well-known toxicity profile (Shefet-Carasso
and Benhar, 2015). Repeated studies, however, have shown that the
actual concentration of the cytotoxic payload in tumour cells is
minimal with only 1–2% of the administered dose reaching the
tumour (Teicher and Chari, 2011). It is evident that the optimal
chemotherapy drug used should be extremely potent, being
effective at picomolar or nanomolar concentrations.
There are two main categories of cytotoxic drugs used in ADC
development: microtubule inhibitors and DNA-damaging drugs.
Auristatins block tubulin assembly and cause G2/M phase cell
cycle arrest; they are the most commonly used payloads,
accounting for a majority of cytotoxic payloads used in ADCs
currently investigated (Sapra and Shor, 2013; Bouchard et al, 2014).
Monomethyl auristatin E, an auristatin derivative (MMAE) is the
cytotoxic payload of brentuximab vendotin and has a free drug
IC50: 10
 11–10 9 allowing it to be effective in the low nanomolar
range (Gerber et al, 2009). Maytansinoids, another class of tubulin
inhibitors, have also been used successfully in the ADC develop-
ment. The cytotoxic payload of trastuzumab emtansine (T-DM1)
DM1 is a highly potent maytansinoid, developed by Immunogen,
with a free drug IC50: 10
 11–10 9. Another maytansinoid drug,
DM4 incorporated on SAR3419, is being investigated in phase II
trials exhibiting significant ‘bystander effect’ as the ADC’s
metabolites have lipophilic properties allowing crossing of the
cellular membrane (Blanc et al, 2011). Tubulysins are a promising
new class of tubulin inhibitors. Tubulisin analogues were
successfully conjugated to trastuzumab forming a stable and
potent ADC (Cohen et al, 2014). The DNA-damaging agents have
the ability to be active throughout the different cell cycle phases.
Duocarmycin is a powerful cytotoxic alkylating compound that
binds to the minor groove of DNA and has shown activity against
various multidrug-resistant models. Duocarmycin-based ADCs are
currently under investigation in a phase 1 trial setting conjugated
to the anti-HER-2 antibody, trastuzumab (Van Herpen et al, 2015).
Calicheamicin is a potent antitumour antibiotic that causes
double-strand DNA breaks and rapid cell death by binding to the
DNA’s minor groove. It is less dependent on cell cycle progression
making it potentially useful against TICs who have lower rates of
proliferation (Gupta et al, 2009; Sapra et al, 2011). Gemtuzumab
ozogamicin and other ADCs such as inotuzumab ozogamicin in
non-Hodgkin lymphoma and MDX-1203 in renal cancer are using
these agents (Owonikoko et al, 2014).
A potential new drug under investigation is a-amanitin, an
RNA polymerase II inhibitor in the picomolar range, derived from
the mushroom, Amanita phalloides (Moldenhauer et al, 2012).
Other topoisomerase inhibitors under investigation is the SN38,
the active metabolite of irinotecan (Palakurthi, 2015). Another new
category is the pyrrolobenzodiazepines (PBDs) that bind to
discrete DNA sequences causing lethal lesions and have interest-
ingly not been found to have cross-resistance with common
chemotherapeutic agents (Bouchard et al, 2014).
A different approach, but in line with ADC principles, are the
radioimmunoconjugates where radionuclides are the cytotoxic
payloads linked to monoclonal antibodies. Two radioimmunocon-
jugates targeting CD20 have been approved for treatment of
refractory HodHL, (Yttrium-90-ibritumomab tiuxetan and iodine-
131-tositumomab). Despite its efficacy due to under-utilisation
tositumomab manufacturer has discontinued its production. In
solid tumours, radioimmunoconjugates are being investigated,
particularly in treating minimal residual disease in prostate and
colorectal cancer among others (Kraeber-Bodere et al, 2014).
CLINICAL EXPERIENCE
T-DM1, Kadcyla. The only ADC licensed in non-haematological
malignancies is ado-trastuzumab-emtansine (T-DM1, Kadcyla,
Roche, Genentech), the antibody used is the well-known
trastuzumab, a humanised IgG1 anti-HER-2 Ab linked with a
stable non-cleavable linker to the maytansinoid DM1 (LoRusso
et al, 2011; Verma et al, 2012). T-DM1 has been approved in the
second line setting by the FDA in 2013 for HER-2-positive patients
who had previously received treatment with trastuzumab and
taxane chemotherapy. T-DM1 has an overall tolerable toxicity
profile with most common adverse events being fatigue, transa-
minitis, nausea, thrombocytopenia and rash. In USA, T-DM1
carries black box warnings for hepatotoxicity, embryo-fetal and
cardiac toxicity Po0.001) (Verma et al, 2012).
T-DM1 is also being investigated as a single agent comparted to
docetaxel in previously treated gastric cancer with results expected
in 2015 (GATSBY trial, NCT01641939) (Shah, 2015).
Brentuximab vedotin, Adcetris. Brentuximab vedotin (BV,
Adcetris, Seattle Genetics) is composed of an anti-CD30 mAb
connected with a cleavable peptide to the highly potent tubulin
inhibitor MMAE discussed previously. CD30 is a member of the
tumour necrosis factor (TNF) family identified on Reed–Sternberg
cells of classical Hodgkin lymphoma (HL). Binding of BV to the
cell surface will lead to internalisation and lysosomal proteolytic
cleavage of the linker releasing the MMAE (Senter and Sievers,
2012; Sievers and Senter, 2013).
BV has gained approval for the treatment of patients with
relapsed or refractory CD30þ HL following autologous stem cell
transplant (ASCT) or patients not legible for ASCT who have failed
at least two other chemotherapy treatments. BV has also been
approved for patients with anaplastic large cell lymphoma (ALCL)
as a second line. The accelerated approval for Hodgkin’s
lymphoma was based on a single-arm phase II clinical trial, where
there was a 73% response rate, 32% complete remission and a
median duration 20.5 months (Younes et al, 2012). The indication
for ALCL was established based on the impressive results of the
phase II study. Patients at this study had an 86% overall response
rate and 54% complete responses (Pro et al, 2012). The most
common adverse reactions were peripheral sensory neuropathy,
neutropenia, fatigue, nausea and thrombocytopenia. In USA, BV
carries a black box warning for progressive multifocal leukoence-
phalopathy (Younes et al, 2012).
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Gemtuzumab ozogamicin, Mylotarg. Gemtuzumab ozoogamicin
(GO, Mylotarg, Pfizer) was the first ADC to be approved by the
FDA in 2000. It was licensed as a monotherapy in patients over the
age of 60 with acute myelogenous leukemia (AML) who were not
candidates for cytotoxic chemotherapy. GO consisted of a
humanised IgG4 mAb directed against CD33 a surface antigen
present in 85–90% of AML linked to a calicheamicin cytotoxin with
positive results coming from the first single-agent phase II studies
achieving 30% remissions (Tsimberidou et al, 2006). In 2010, the
results of a post-approval phase III study showed no clinical benefit.
In fact, the patients in the GO arm had a higher risk of fatal AEs and
this trial led to the retraction of its FDA licence approval (Petersdorf
et al, 2013). The failures were attributed to an unstable linker
allowing premature release of the cytotoxic payload and to the not-
so-selective antibody target (ten Cate et al, 2009).
More recent trials such as the ALFA-0701 using intermittent
dosing regimens have showed good results, improving event-free
survival and overall survival in patients with AML, reigniting
discussions about the future of GO (Castaigne et al, 2012).
Clinical trial setting. Research in ADCs has been very active with
almost 120 total clinical trials with the majority focusing on
haematological malignancies. Interest in solid tumours is evident
with 52 open phase I/II studies There are approximately 50 unique
ADCs under investigation, with 35 ADCs investigated in solid
tumours (Mullard, 2013).
Putative mechanisms of resistance. Cancer cells under the
pressure of any treatment develop resistance mechanisms that will
allow them to survive. These mechanisms are complex and variable
confronting the ADC in each of its different components, the
cytotoxic drug, the monoclonal antibody or by activating survival
signalling pathways (Shefet-Carasso and Benhar, 2015).
The cytotoxic payload of the ADC is subject to the same
multidrug resistance mechanisms as conventional chemotherapy
drugs. Some of the most commonly used drugs in the new
generation ADCs such as auristatins (MMAE) and calicheamicin
are substrates of P-glycoprotein. Resistance can also emerge from
mechanisms that will limit the intracellular concentration of the
ADC. Barok et al (2014) have described such mechanisms in their
work with T-DM1, that is, downregulation of the target antigen,
reduced internalisation of the ADC, diminished lysosomal
degradation or increased ADC recycling to the cell surface and
masking of the antigen epitope. There is also evidence that
activation of the PI3K/AKT, MEK/ERK and JAK/STAT pathways
leads to increased ADC resistance indicating that a potential way
ahead could be combinations with small molecule inhibitors
(Shefet-Carasso and Benhar, 2015). Clonal expansion of resistant
cells and intratumoural heterogeneity representing populations of
cells that are resistant de novo within the same tumour, are likely to
influence resistance to ADCs (Gerlinger et al, 2012).
CONCLUSION: FUTURE PROSPECTS
Predictive biomarkers are essential to ensure we are offering the most
effective treatments to the group of patients most likely to benefit
from them. Development of specific tests that will determine the
chances of responding to treatment to an ADC by investigating the
level of expression of the target antigen similar to the immunohis-
tochemical (IHC) confirmation of HER-2 expression are already
being explored (Mack et al, 2014). Efforts are ongoing in order to
move away from IHC-based techniques that require tissue biopsy and
use circulating tumour cells or imaging techniques to identify the
patient population more likely to respond (Mack et al, 2014).
Another approach to ADCs is to use high-affinity molecules like
folic acid or growth hormones as cytotoxic payload carriers or small
antibody fragments such as diabodies or minibodies. The rationale
behind this approach is that it might result in more effective drug
delivery and increased antitumour activity. However, this approach
will also limit the pharmacokinetic benefits of an ADC resulting in
more rapid clearance and larger volume of distribution.
Combination strategies are actively explored in many ongoing
clinical trials. T-DM1 is being investigated in combination with
pertuzumab (Phillips et al, 2014). Other combinations of ADCs
investigated are with conventional chemotherapies, for example,
brentuximab with modified AVD, PI3K inhibitors like BYL719
with T-DM1 or with TKI inhibitors like neratinib.
There remain major hurdles that ADCs need to overcome: low
delivery efficiency, target antigens expressed in normal tissues, the
heterogeneity of target antigen expression in the tumour and more
(Teicher and Chari, 2011). The future of ADCs seems promising as
the combination of new linker technologies and more powerful
cytotoxic payloads leads to the emergence of more stable and
effective ADCs.
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